The development of a novel PARP inhibitor with potent antitumor activity in various tumor xenograft models

被引：0
|
作者：
Park, Ji-Seon [1 ]
Kim, Jang-Hyun [1 ]
Cheon, Kwang-Woo [1 ]
Cho, Bo-Young [1 ]
Kim, Kang-Jeon [1 ]
Lee, Han-Chang [1 ]
Kim, Young-Cheol [1 ]
Oh, Hyung-Chan [1 ]
Lee, Hyun-Ho [1 ]
Kim, Jeong-Min [1 ]
机构：
[1] JEIL Pharm, Yongin, South Korea
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-825
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
825
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Plocabulin, a tubulin inhibitor, presents antitumor activity in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor (GIST)
    Wozniak, Agnieszka
    Wang, Yannick
    Wellens, Jasmien
    Gebreyohannes, Yemarshet K.
    Jose Guillen, Maria
    Galmarini, Carlos M.
    Aviles, Pablo M.
    Debiec-Rychter, Maria
    Sciot, Raf
    Schoffski, Patrick
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms
    Scott, Aaron J.
    Arcaroli, John J.
    Bagby, Stacey M.
    Yahn, Rachel
    Huber, Kendra M.
    Serkova, Natalie J.
    Nguyen, Anna
    Kim, Jihye
    Thorburn, Andrew
    Vogel, Jon
    Quackenbush, Kevin S.
    Capasso, Anna
    Schreiber, Anna
    Blatchford, Patrick
    Klauck, Peter J.
    Pitts, Todd M.
    Eckhardt, S. Gail
    Messersmith, Wells A.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (10) : 2112 - 2122
  • [33] A new microtubulin inhibitor with vascular disruption activity, EPC2407, enhances the antitumor activity of antiangiogenic or chemotherapeutic agents in xenograft tumor models
    Tseng, Beb
    May, Chris
    Whisnant, John
    Anthony, Stephen
    Von Hoff, Daniel
    Gonzales, Paul
    Chavira, Bernardo
    Gately, Stephen
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3434S - 3434S
  • [34] Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models
    Kadhim, SA
    Bowlin, TL
    Wand, WR
    Angers, EG
    Bibeau, L
    DeMuys, JM
    Bednarski, K
    Cimpoia, A
    Attardo, G
    CANCER RESEARCH, 1997, 57 (21) : 4803 - 4810
  • [35] Antitumor activity of MGI 114 against two human prostate tumor xenograft models
    Mangold, G
    MacDonald, J
    Von Hoff, D
    Weitman, S
    ANNALS OF ONCOLOGY, 1998, 9 : 37 - 37
  • [36] Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models
    Michael H. Woo
    Jennifer K. Peterson
    Catherine Billups
    Hua Liang
    Mary-Ann Bjornsti
    Peter J. Houghton
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 411 - 419
  • [37] Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models
    Woo, MH
    Peterson, JK
    Billups, C
    Liang, H
    Bjornsti, MA
    Houghton, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (05) : 411 - 419
  • [38] In vivo activity of a Raf kinase inhibitor in human tumor xenograft models.
    Eberwwin, D
    Gianpaolo-Ostravage, C
    Riedl, B
    Lowinger, T
    Chien, DS
    Wood, J
    Lyons, J
    Hibner, B
    CLINICAL CANCER RESEARCH, 2000, 6 : 4547S - 4547S
  • [39] The application of zebrafish patient-derived xenograft tumor models in the development of antitumor agents
    Li, Xiang
    Li, Minyong
    MEDICINAL RESEARCH REVIEWS, 2023, 43 (01) : 212 - 236
  • [40] Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
    Huynh, Hung
    Ong, Richard
    Zopf, Dieter
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
12345